These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 25732907

  • 1. Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.
    Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM.
    Pharmacogenomics J; 2015 Oct; 15(5):461-6. PubMed ID: 25732907
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.
    Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, F Samer C, Lieberman JA, Villard J.
    Pharmacogenomics J; 2019 Apr; 19(2):211-218. PubMed ID: 29298994
    [Abstract] [Full Text] [Related]

  • 3. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.
    Legge SE, Walters JT.
    Pharmacogenomics; 2019 Mar; 20(4):279-290. PubMed ID: 30767710
    [Abstract] [Full Text] [Related]

  • 4. Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C.
    McKnight C, Guirgis H, Votolato N.
    Am J Psychiatry; 2011 Oct; 168(10):1120. PubMed ID: 21969051
    [No Abstract] [Full Text] [Related]

  • 5. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.
    Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B.
    Arch Gen Psychiatry; 2001 Jan; 58(1):93-4. PubMed ID: 11146763
    [No Abstract] [Full Text] [Related]

  • 6. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis.
    Tiwari AK, Need AC, Lohoff FW, Zai CC, Chowdhury NI, Müller DJ, Putkonen A, Repo-Tiihonen E, Hallikainen T, Yağcıoğlu AE, Tiihonen J, Kennedy JL, Meltzer HY.
    Mol Psychiatry; 2014 Apr; 19(4):403-5. PubMed ID: 23752246
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.
    Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR.
    J Clin Psychiatry; 2011 Apr; 72(4):458-63. PubMed ID: 20868635
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia.
    Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ.
    Arch Gen Psychiatry; 1990 Oct; 47(10):945-8. PubMed ID: 2222133
    [Abstract] [Full Text] [Related]

  • 12. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.
    Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D.
    Br J Psychiatry; 1996 Oct; 169(4):483-8. PubMed ID: 8894200
    [Abstract] [Full Text] [Related]

  • 13. How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
    Verbelen M, Lewis CM.
    Pharmacogenomics; 2015 Oct; 16(9):915-7. PubMed ID: 26122865
    [No Abstract] [Full Text] [Related]

  • 14. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry.
    Konte B, Walters JTR, Rujescu D, Legge SE, Pardiñas AF, Cohen D, Pirmohamed M, Tiihonen J, Hartmann AM, Bogers JP, van der Weide J, van der Weide K, Putkonen A, Repo-Tiihonen E, Hallikainen T, Silva E, Ingimarsson O, Sigurdsson E, Kennedy JL, Sullivan PF, Rietschel M, Breen G, Stefansson H, Stefansson K, Collier DA, O'Donovan MC, Giegling I.
    Transl Psychiatry; 2021 Apr 12; 11(1):214. PubMed ID: 33846298
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine.
    Spencer BW, Prainsack B, Rujescu D, Giegling I, Collier DA, Gaughran F, MacCabe JH, Barr CL, Sigurdsson E, Stovring H, Malhotra AK, Curran SR, CRESTAR Consortium.
    Pharmacogenomics; 2013 Nov 12; 14(15):1907-14. PubMed ID: 24236489
    [Abstract] [Full Text] [Related]

  • 18. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
    Schulte PFJ, Veerman SRT, Bakker B, Bogers JPAM, Jongkind A, Cohen D.
    Schizophr Res; 2024 Jun 12; 268():74-81. PubMed ID: 37770377
    [Abstract] [Full Text] [Related]

  • 19. [Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model].
    Güzelcan Y, Scholte WF.
    Tijdschr Psychiatr; 2006 Jun 12; 48(4):295-302. PubMed ID: 16955993
    [Abstract] [Full Text] [Related]

  • 20. Clozapine-associated agranulocytosis: risk and aetiology.
    Krupp P, Barnes P.
    Br J Psychiatry Suppl; 1992 May 12; (17):38-40. PubMed ID: 1418887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.